All TreatGx users now have access to the updated Generalized Anxiety Disorder treatment algorithm. This comprehensive update incorporates information from the most recent clinical guidelines and literature from the American Family Physician[1], the BMJ[2], Lancet[3], and others.
Highlights of the update include:
- 8 new medication treatment options that have been added based on the latest evidence for efficacy and safety – buspirone, clonazepam, diazepam, fluoxetine, hydroxyzine, imipramine, mirtazapine, and quetiapine
- Side effect profiles for all medication options
- Users can choose whether or not to view optional, guideline-supported benzodiazepine dosing for short-term use
In addition to the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions, the comprehensive update includes informative notes on level of evidence, co-morbid conditions, and suitability of medications for augmentation use.
References:
- Locke AB, Kirst N, Shultz CG: Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician 2015, 91(9):617-624.
- Gale C: Generalised anxiety disorder. BMJ Best Practice 2020.
- Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N: Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019, 393(10173):768-777.